In The Lancet, Xiaohua Wu and colleagues 5 present the COMPASSION-16 trial: a phase 3, double-blind, multicentre randomised controlled trial assessing the efficacy of cadonilimab, a bispecific ...
Some results have been hidden because they may be inaccessible to you